Compare Heron Therapeutics Inc (HRTX) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Microchip Technology Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Microchip Technology Inc. trades at $76.5 (market cap $41.01B). The key difference: Microchip Technology Inc. is far larger — about 603× Heron Therapeutics Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Microchip Technology Inc. for 62 Days on average.
| HRTX | MCHP | |
|---|---|---|
Market Cap | $68.01M | $41.01B |
Volume | 1,891,941 | 9,972,516 |
Sector | Health | Technology |
52-Week High | $1.49 | $102.97 |
52-Week Low | $0.27 | $49.02 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $174.75M | $46.13B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Microchip Technology (MCHP) trades at $78.02, down 3.99% on the day, amid a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined sharply in 2025 to $4.40B, resulting in a net loss, but 2026 projections show recovery. Analyst consensus is strongly bullish with a $110.50 price target. Recent news highlights expansion in Ethernet and power portfolios, plus the acquisition of Hailo to bolster edge AI capabilities.
MCHP's outlook is supported by robust analyst buy ratings and exposure to growing AI and data center demand. However, high valuation multiples, significant debt, and cyclical semiconductor risks pose challenges. Earnings growth in 2026 will be critical to justifying its premium valuation and driving shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
